Table 4.
Multivariate analysis of risk factors for 14-day mortality.
| Variable | P-value | OR (95% CI) |
|---|---|---|
| Overall mortality | ||
| Diabetes mellitus | 0.03 | 1.97 (1.06–3.68) |
| Nosocomial acquisition | 0.17 | 1.71 (0.80–3.69) |
| Catheter-related infection | 0.05 | 0.13 (0.02–0.99) |
| Pneumonia | <0.01 | 3.95 (1.98–7.91) |
| APACHE II score > 15 | 0.04 | 2.24 (1.02–4.89) |
| Timing of initiating glycopeptide therapy | ||
| Before preliminary BC report indicated SLO growth and within 24 h after BC indicated SLO Growth | 0.40 | 1.37 (0.66–2.84) |
| Infection-related mortality | ||
| Catheter-related infection | 0.16 | 0.23 (0.03–1.78) |
| Pneumonia | <0.01 | 4.47 (2.09–9.58) |
| APACHE II score > 15 | 0.02 | 2.81 (1.19–6.65) |
| Timing of initiating glycopeptide therapy | ||
| Before preliminary BC report indicated SLO growth and within 24 h after BC indicated SLO Growth | 0.90 | 0.95 (0.41–2.21) |
BC: blood culture; MRSA: methicillin-resistant S. aureus; SLO: Staphylococcus-like organism.